Table 4.
Effects of Tirofiban treatment on treatment effects in patients with different ischemic stroke etiology.
| Tirofiban | Without tirofiban | P value | Adjusted OR (95% CI) and P value | |
|---|---|---|---|---|
| ALL PATIENTS* | ||||
| Neurological improvement at 24 h | 16/71 (22.5) | 37/124 (29.8) | 0.270 | 0.682 (0.342–1.364), 0.279 |
| Neurological improvement at 3d | 20/71 (28.2) | 46/124 (37.1) | 0.205 | 0.674 (0.354–1.283), 0.229 |
| Neurological improvement at discharge | 42/71 (59.2) | 59/124 (47.6) | 0.120 | 1.467 (0.802–2.684), 0.213 |
| LARGE ARTERY ATHEROSCLEROSIS# | ||||
| Neurological improvement at 24 h | 11/39 (28.2) | 10/56 (17.9) | 0.232 | 2.598 (0.850–7.942), 0.094 |
| Neurological improvement at 3d | 13/39 (33.3) | 14/56 (25.0) | 0.376 | 1.897 (0.696–5.172), 0.211 |
| Neurological improvement at discharge | 23/39 (59.0) | 23/56 (41.1) | 0.086 | 2.157 (0.869–5.358), 0.098 |
| CARDIOEMBOLISM$ | ||||
| Neurological improvement at 24 h | 3/28 (10.7) | 26/56 (46.4) | 0.001 | 0.185 (0.047–0.726), 0.016 |
| Neurological improvement at 3d | 6/28 (21.4) | 30/56 (53.6) | 0.005 | 0.268 (0.087–0.825), 0.022 |
| Neurological improvement at discharge | 17/28 (60.7) | 33/56 (58.9) | 0.875 | 0.990 (0.334–2.931), 0.986 |
*
Adjusted for age, gender, NIHSS on admission, previous TIA/stroke, intravenous thrombolysis.
#
Adjusted for age, gender, NIHSS on admission, smoking, diabetes mellitus.
$
Adjusted for age, gender, NIHSS on admission, smoking, previous TIA/stroke, intravenous thrombolysis.